Mitochondria-Related Genome-Wide Mendelian Randomization Identifies Putatively Causal Genes for Neurodegenerative Diseases
AffiliationsDOI: 10.1002/mds.30123
- PMID: 39838927
Abstract
Background: Mitochondrial dysfunction is increasingly recognized as a key factor in neurodegenerative diseases (NDDs), underscoring the therapeutic potential of targeting mitochondria-related genes. This study aimed to identify novel biomarkers and drug targets for these diseases through a comprehensive analysis that integrated genome-wide Mendelian randomization (MR) with genes associated with mitochondrial function.
Methods: Using existing publicly available genome-wide association studies (GWAS) summary statistics and comprehensive data on 1136 mitochondria-related genes, we initially identified a subset of genes related to mitochondrial function that exhibited significant associations with NDDs. We then conducted colocalization and summary-data-based Mendelian randomization (SMR) analyses using expression quantitative trait loci (eQTL) to validate the causal role of these candidate genes. Additionally, we assessed the druggability of the encoded proteins to prioritize potential therapeutic targets for further exploration.
Results: Genetically predicted levels of 10 genes were found to be significantly associated with the risk of NDDs. Elevated DMPK and LACTB2 levels were associated with increased Alzheimer's disease risk. Higher expression of NDUFAF2, BCKDK, and MALSU1, along with lower TTC19, raised Parkinson's disease risk. Higher ACLY levels were associated with both amyotrophic lateral sclerosis and multiple sclerosis (MS) risks, while decreased MCL1, TOP3A, and VWA8 levels raised MS risk. These genes primarily impact mitochondrial function and energy metabolism. Notably, several druggable protein targets identified are being explored for potential NDDs treatment.
Conclusions: This data-driven MR study demonstrated the causal role of mitochondrial dysfunction in NDDs. Additionally, this study identified candidate genes that could serve as potential pharmacological targets for the prevention and treatment of NDDs. © 2025 International Parkinson and Movement Disorder Society.
Looks like the energy supply has a causal role in many diseases.
- Forums
- ASX - By Stock
- ATH
- Mitochondrial genes related to neurodegenerative diseases
ATH
alterity therapeutics limited
Add to My Watchlist
11.1%
!
1.0¢

Mitochondrial genes related to neurodegenerative diseases
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.001(11.1%) |
Mkt cap ! $91.27M |
Open | High | Low | Value | Volume |
0.9¢ | 1.0¢ | 0.9¢ | $41.54K | 4.357M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
35 | 11136808 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 4729475 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
33 | 11051808 | 0.009 |
18 | 11245794 | 0.008 |
16 | 10257963 | 0.007 |
13 | 8003518 | 0.006 |
6 | 3350001 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 4726475 | 9 |
0.011 | 5569414 | 14 |
0.012 | 23020191 | 27 |
0.013 | 6944325 | 13 |
0.014 | 12788180 | 6 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online